Abstract

Tissue factor pathway inhibitor (TFPI) is a plasma serine protease inhibitor that directly inhibits coagulation factor Xa and regulates blood coagulation via inhibition of factor VIIa-tissue factor enzymatic activity. We previously demonstrated that >90% of TFPI bound to a single population of low affinity binding sites on hepatoma cells (2 x 10(6) sites/cell, Kd = 30 nM), and, that following binding, the low density lipoprotein receptor-related protein (LRP) mediated TFPI uptake and degradation. We subsequently reported heparan sulfate proteoglycans (HSPGs) constitute a second receptor system involved in TFPI catabolism. In the present study, mouse embryonic fibroblasts heterozygous and homozygous-negative for disruption of the LRP gene were used to further examine the roles of LRP and HSPGs in TFPI endocytosis. We demonstrate that LRP is absolutely required for degrading 125I-TFPI. LRP heterozygous and homozygous-negative cells bind 125I-TFPI similarly, and the 39-kDa protein, an inhibitor of all known ligand interactions with LRP, does not alter 125I-TFPI binding to these cells. TFPI can be cross-linked to LRP on [35S]cysteine-labeled hepatoma and LRP-heterozygous cells but not LRP-negative cells. When HSPGs are blocked with protamine, 125I-TFPI binds in a 39-kDa protein-inhibitable manner to 41,000 high affinity sites/hepatoma cell (Kd = 2.3 nM). Blockade of HSPGs with protamine results in significantly more 125I-TFPI degradation by LRP-positive cells. TFPI can be cross-linked to LRP in the absence and presence of protamine. However, in the presence of protamine, relative to the total pool of cross-linked proteins, 5-fold more TFPI is cross-linked to LRP. Finally, we show TFPI inhibits 125I-alpha2-macroglobulin-methylamine binding to hepatoma cells and that carboxyl-terminal residues 115-319 of the 39-kDa protein inhibit both 125I-TFPI degradation and binding when binding conditions contain protamine. Together, our results suggest that while the majority of TFPI binds to cell surface HSPGs, LRP can function independently from HSPGs in the binding and uptake of TFPI.

Highlights

  • § Supported in part by Cardiovascular Training Grant T32-HL07275. ʈ Lucille P

  • These high molecular mass bands migrated to the identical position as that seen in cell lysates immunoprecipitated with anti-lipoprotein receptor-related protein (LRP) antibody (Fig. 1, A and B), implying Tissue factor pathway inhibitor (TFPI) and the 39-kDa protein are binding to LRP

  • We previously demonstrated that LRP mediates the cellular degradation of 125I-TFPI since degradation was inhibited by antibodies directed against LRP and by the 39-kDa protein [10]

Read more

Summary

Introduction

§ Supported in part by Cardiovascular Training Grant T32-HL07275. ʈ Lucille P. Supported by Grant HL20948, the Perot Family Foundation, and the Syntex Scholar Program. Numerous studies have found that exogenously added 39-kDa protein inhibits the binding and/or cellular uptake of all ligands by LRP [1]. We previously reported [10] that LRP mediated the uptake and cellular degradation of tissue factor pathway inhibitor (TFPI), a 42-kDa plasma glycoprotein that inhibits both coagulation factor Xa and tissue factor-initiated blood coagulation [16]. We reported that LRP was not the major cell surface TFPI receptor since the 39-kDa protein did not inhibit 125I-TFPI binding [10]. Domains on the 39-kDa protein required for inhibiting TFPI degradation and cross-competition studies between TFPI and previously characterized LRP-ligands have been examined

Objectives
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.